S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

AcelRx Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $1.91
50-Day Range
MA: $1.47
52-Week Range
Now: $1.91
Volume6.37 million shs
Average Volume10.70 million shs
Market Capitalization$172.81 million
P/E RatioN/A
Dividend YieldN/A
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
AcelRx Pharmaceuticals logo


Overall MarketRank

1.30 out of 5 stars

Medical Sector

688th out of 1,923 stocks

Pharmaceutical Preparations Industry

348th out of 773 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ACRX



Sales & Book Value

Annual Sales$2.29 million
Book Value($0.52) per share


Net Income$-53,240,000.00
Net Margins-890.43%


Market Cap$172.81 million
Next Earnings Date3/15/2021 (Estimated)
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

How has AcelRx Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACRX stock has increased by 56.6% and is now trading at $1.91.
View which stocks have been most impacted by COVID-19

Is AcelRx Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AcelRx Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRX, but not buy additional shares or sell existing shares.
View analyst ratings for AcelRx Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AcelRx Pharmaceuticals?

Wall Street analysts have given AcelRx Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AcelRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AcelRx Pharmaceuticals

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) released its quarterly earnings data on Tuesday, November, 10th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The specialty pharmaceutical company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $6.15 million.
View AcelRx Pharmaceuticals' earnings history

What guidance has AcelRx Pharmaceuticals issued on next quarter's earnings?

AcelRx Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Thursday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.4-5.4 million, compared to the consensus revenue estimate of $7.25 million.

What price target have analysts set for ACRX?

3 analysts have issued 1-year target prices for AcelRx Pharmaceuticals' shares. Their forecasts range from $0.84 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $5.28 in the next year. This suggests a possible upside of 176.4% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 52, Pay $896.02k)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 57, Pay $660.85k)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 51, Pay $591.01k)
  • Mr. Lawrence G. Hamel, Consultant (Age 68, Pay $468.76k)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 57, Pay $469k)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Dfpg Investments LLC (0.06%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including Dfpg Investments LLC. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Adrian Adams, Mark G Edwards, Pamela P Palmer, Raffi Asadorian, and Vincent J Angotti.
View insider buying and selling activity for AcelRx Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.91.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $172.81 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 99 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.